Malignant neoplasm of stomach

Imfinzi Gains FDA Approval for Early Gastric and GEJ Cancers; BiomX Nebulizer Faces FDA Scrutiny

3 weeks ago talkbio0Tagged Approved, BiomX, Clinical, Imfinzi, Malignant neoplasm of cardioesophageal junction of stomach, Malignant neoplasm of stomach, Nebulizers, perioperative, United States Food and Drug Administration

Imfinzi; FDA approval; gastric cancer; gastroesophageal cancer; perioperative; BiomX; nebulizer; clinical hold

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

4 weeks ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

4 weeks ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

Cogent Hits Unprecedented Efficacy in Rare Stomach Cancer, Clearing Path to FDA

1 month ago talkbio0Tagged bezuclastinib, Cogent Biosciences, Effectiveness, Frequency of Responses, Gastrointestinal Stromal Tumors, Infrequent, Malignant neoplasm of stomach, Progression-Free Survival, second-line treatment, Submission, United States Food and Drug Administration

Cogent Biosciences; bezuclastinib; unprecedented efficacy; rare stomach cancer; gastrointestinal stromal tumor (GIST); FDA submission; second-line treatment; objective response rate; progression-free survival

Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial

2 months ago talkbio0Tagged Arcus, domvanalimab, Gilead, Malignant neoplasm of stomach, TIGIT gene, zimberelimab

Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

2 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates

Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

2 months ago talkbio0Tagged Advanced phase, Bristol Myers Squibb, EP4 antagonist, EP4 Antagonist ONO-4578, Episodic, HER2-negative, Malignant neoplasm of stomach, nivolumab, Opdivo, Pharmacotherapy, Phase 2, Progression-Free Survival

ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent

Survival Benefit of Amgen’s Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

3 months ago talkbio0Tagged amgen, Attenuated by (contextual qualifier), bemarituzumab, Benefit, final analysis, FORTITUDE-101, FORTITUDE-102, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Zai Lab

Amgen; bemarituzumab; gastric cancer; Phase 3 trial; overall survival; attenuated benefit; final analysis; FORTITUDE-101; FORTITUDE-102; Zai Lab; Opdivo; nivolumab